Join to View Full Profile
269 Campus Dr# DivisionStanford, CA 94305
Phone+1 650-723-6661
Dr. Gubens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2008 - 2011
University of California (San Francisco)Residency, Internal Medicine, 2005 - 2008
Stanford University School of MedicineClass of 2005
Certifications & Licensure
CA State Medical License 2007 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Start of enrollment: 2012 Dec 11
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
- Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Start of enrollment: 2020 May 29
Publications & Presentations
PubMed
- Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Karmugi Balaratnam, Eduardo Cardenas
Journal for Immunotherapy of Cancer. 2025-03-28 - Proceedings of the 1st biannual bridging the gaps in lung cancer conference.Narjust Florez, Sandip P Patel, Heather Wakelee, Lyudmila Bazhenova, Erminia Massarelli
The Oncologist. 2025-02-06 - Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.Howard J Lee Jr, John Boscardin, Louise C Walter, Alexander K Smith, Harvey J Cohen
The Oncologist. 2024-12-09
Press Mentions
Conference Coverage: NCCN Clinical UpdatesApril 16th, 2019
ASCO 2017 – Lung Cancer – A Practice Change for ALK+ Lung Cancer Patients, Alecensa for First Line TreatmentAugust 9th, 2017- ASCO 2017 – Lung Cancer – Sequencing Treatments for ALK+ Lung Cancer in a Crowded Field – Is There a Place for Lorlatinib?August 9th, 2017
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
